PV Bulletin

Product Management Service (PMS) public API beta release - Technical registration requirements

EMA released updated technical registration requirements for the PMS public API beta release, affecting marketing authorization holders' data management systems.

Primary source: Questions and answers on the refusal of a change to the marketing authorisation for Hetlioz (tasimelteon) (II-40)

PV Impact Brief

Urgency: HighConfidence: high

What changed

The EMA released updated technical registration requirements for the PMS public API, mandating MAHs to review and ensure system compatibility with these requirements for effective data submission.

Why it matters

Compliance with the new API requirements is necessary for accurate pharmacovigilance reporting, including vital ICSR/E2B identifiers, impacting the integrity of regulatory data management.

Action needed

MAHs and technical teams must review the revised API registration requirements and implement necessary system updates to comply by the established timelines.

Relevant for
Regulatory Intelligence LeadQPPV
Processes impacted
Country ComplianceICSR
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Technical Guidance
Policy status
beta
Publication date
12 June 2026
Policy change
EMA released updated technical registration requirements and API documentation (Chapter 1, Annex B) for the Product Management Service (PMS) public API beta release. This is part of the ongoing implementation of ISO IDMP standards for the identification of medicinal products in Europe.

Key changes

Release of technical specifications for public PMS API registration; Annex B updates for ISO IDMP implementation; registration requirements for beta and production environments for substance and product data management.

Affected workflows

Country ComplianceICSR

Responsible groups

Regulatory OperationsITPV Data Management

PV impact

Marketing Authorization Holders (MAHs) and technical teams responsible for regulatory data management must review the new registration requirements to ensure their systems can integrate with the PMS API. This affects the submission of master data which is critical for pharmacovigilance reporting (e.g., ICSR/E2B identifiers).

View regulator source

Source document details

Extracted documents

Evidence and confidence

Confidence: highSource updated: Jun 12, 2026

Full briefing

Practical implication

MAHs and technical teams must review the revised API registration requirements and implement necessary system updates to comply by the established timelines.

The EMA has updated the technical registration requirements and API documentation for the PMS public API beta release. Marketing Authorization Holders (MAHs) must review these requirements to ensure their systems are compatible with the API, which is critical for pharmacovigilance reporting, particularly regarding ICSR/E2B identifiers.

What changed: The EMA released updated technical registration requirements for the PMS public API, mandating MAHs to review and ensure system compatibility with these requirements for effective data submission.

Why it matters: Compliance with the new API requirements is necessary for accurate pharmacovigilance reporting, including vital ICSR/E2B identifiers, impacting the integrity of regulatory data management.

Practical implication: MAHs and technical teams must review the revised API registration requirements and implement necessary system updates to comply by the established timelines.

View original source

Published from the Firecrawl policy change extraction pipeline.

#Safety Signals#European Medicines Agency (EMA)#Reporting Requirement#policy-change#firecrawl-policy-agent#Technical Guidance#beta

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Atellica CH Revised C-Reactive Protein (RCRP) Safety Information - Siemens Healthcare Diagnostics

Urgency: High

Laboratories must implement the safety measures as indicated by the action registration number R2625739, effective from the notice date of September 7, 2026.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward